170 related articles for article (PubMed ID: 37426835)
41. Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).
Lee EJ; Izak M; Bussel JB
Br J Haematol; 2020 Apr; 189(2):379-382. PubMed ID: 31900937
[TBL] [Abstract][Full Text] [Related]
42. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
43. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
[TBL] [Abstract][Full Text] [Related]
44. Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
Tamary H; Roganovic J; Chitlur M; Nugent DJ
Ann Hematol; 2010 Jul; 89 Suppl 1(Suppl 1):5-10. PubMed ID: 20358200
[TBL] [Abstract][Full Text] [Related]
45. Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials.
Ali MA; Anwar MY; Aiman W; Dhanesar G; Omar Z; Hamza M; Zafar M; Rengarajan HK; Maroules M
J Xenobiot; 2023 Jan; 13(1):29-41. PubMed ID: 36810430
[TBL] [Abstract][Full Text] [Related]
46. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB;
Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486
[TBL] [Abstract][Full Text] [Related]
47. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
Iino M; Sakamoto Y; Sato T
Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
[TBL] [Abstract][Full Text] [Related]
48. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
Lv Y; Shi H; Liu H; Zhou L
Front Immunol; 2022; 13():953716. PubMed ID: 36003388
[TBL] [Abstract][Full Text] [Related]
49. Investigational drugs for immune thrombocytopenia.
Provan D; Newland AC
Expert Opin Investig Drugs; 2022 Jul; 31(7):715-727. PubMed ID: 35531637
[TBL] [Abstract][Full Text] [Related]
50. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.
Rovó A; Cantoni N; Samii K; Rüfer A; Koenen G; Ivic S; Cavanna D; Benz R
PLoS One; 2022; 17(4):e0267342. PubMed ID: 35446925
[TBL] [Abstract][Full Text] [Related]
51. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
[TBL] [Abstract][Full Text] [Related]
52. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
53. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
Mingot-Castellano ME; Caparrós IS; Fernández F; Perera-Alvarez MDM; Jimenez-Bárcenas R; Casaus García A; González-Silva M; Yera-Cobo M; Nieto-Hernandez MM; Rodríguez-Fernandez MJ; Díaz-Canales D
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):374-380. PubMed ID: 29738335
[TBL] [Abstract][Full Text] [Related]
54. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
[TBL] [Abstract][Full Text] [Related]
55. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
56. A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic.
Alimova M; Sidhom EH; Satyam A; Dvela-Levitt M; Melanson M; Chamberlain BT; Alper SL; Santos J; Gutierrez J; Subramanian A; Grinkevich E; Bricio ER; Kim C; Clark A; Watts A; Thompson R; Marshall J; Pablo JL; Coraor J; Roignot J; Vernon KA; Keller K; Campbell A; Emani M; Racette M; Bazua-Valenti S; Padovano V; Weins A; McAdoo SP; Tam FWK; Ronco L; Wagner F; Tsokos GC; Shaw JL; Greka A
bioRxiv; 2020 Jun; ():. PubMed ID: 32637960
[TBL] [Abstract][Full Text] [Related]
57. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
Ayad N; Grace RF; Al-Samkari H
Pediatr Blood Cancer; 2022 Mar; 69(3):e29447. PubMed ID: 34962697
[TBL] [Abstract][Full Text] [Related]
58. Transient Complete Recovery of Chronic Refractory Idiopathic Thrombocytopenic Purpura after Treatment with Monoclonal Antibody Targeting SARS-CoV-2 Spike Protein.
Gogia P; Xu Y
Case Rep Hematol; 2022; 2022():8335541. PubMed ID: 35685064
[TBL] [Abstract][Full Text] [Related]
59. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
Vibor M; Rogulj IM; Ostojic SK
Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281
[TBL] [Abstract][Full Text] [Related]
60. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review.
Agarwal N; Mangla A
Ther Adv Hematol; 2021; 12():20406207211001139. PubMed ID: 33796239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
